Onychomycosis is the most common nail disorder seen in clinical practice with a prevalence of 8.7%-13.8% in the United States (US). [1][2][3] There has been a trend towards increased racial and ethnic diversity in the United States, with current projections estimating that minority representation will exceed 50% of the population by 2044. 4 Demographic reporting and inclusion of diverse populations within clinical trials is critical to interpret treatment efficacy and prognosis for different groups. A systematic review on racial/ ethnic reporting of dermatology clinical trial participants has been performed, 5 but similar data from onychomycosis clinic trials have not been studied. Our objectives were to systematically review racial/ethnic reporting and representation, as well as, outcomes by race/ethnicity in onychomycosis clinical trials.
| MATERIAL S AND ME THODSPubMed was searched in August 2020 for all peer-reviewed, Englishlanguage onychomycosis clinical trials. The keyword 'onychomycosis' was searched with no date ranges, article type filtered for 'Clinical